C-Rad AB (publ) (CRAD-B.ST)
SEK 29.9
(-0.17%)
SEK 29.9
(-0.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 424.61 Million SEK | 40.91% |
| 2022 | 301.32 Million SEK | 15.38% |
| 2021 | 261.15 Million SEK | 17.83% |
| 2020 | 221.62 Million SEK | 7.9% |
| 2019 | 205.39 Million SEK | 8.04% |
| 2018 | 190.11 Million SEK | 42.81% |
| 2017 | 133.12 Million SEK | 61.06% |
| 2016 | 82.65 Million SEK | 24.93% |
| 2015 | 66.16 Million SEK | 24.38% |
| 2014 | 53.19 Million SEK | 18.11% |
| 2013 | 45.03 Million SEK | 74.72% |
| 2012 | 25.77 Million SEK | 72.88% |
| 2011 | 14.9 Million SEK | 4.74% |
| 2010 | 14.23 Million SEK | 190.57% |
| 2009 | 4.89 Million SEK | 279.42% |
| 2008 | 1.29 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 129.4 Million SEK | 9.66% |
| 2024 Q3 | 100.1 Million SEK | -22.64% |
| 2024 Q1 | 118 Million SEK | -14.74% |
| 2023 Q1 | 84.4 Million SEK | -14.6% |
| 2023 FY | 424.6 Million SEK | 40.91% |
| 2023 Q4 | 138.4 Million SEK | 24.46% |
| 2023 Q2 | 90.6 Million SEK | 7.35% |
| 2023 Q3 | 111.2 Million SEK | 22.74% |
| 2022 Q3 | 83.5 Million SEK | 33.17% |
| 2022 Q1 | 56.3 Million SEK | -27.31% |
| 2022 Q2 | 62.7 Million SEK | 11.37% |
| 2022 FY | 301.32 Million SEK | 15.38% |
| 2022 Q4 | 98.82 Million SEK | 18.35% |
| 2021 Q3 | 63.2 Million SEK | 4.46% |
| 2021 FY | 261.15 Million SEK | 17.83% |
| 2021 Q2 | 60.5 Million SEK | 0.83% |
| 2021 Q1 | 60 Million SEK | -19.28% |
| 2021 Q4 | 77.45 Million SEK | 22.55% |
| 2020 FY | 221.62 Million SEK | 7.9% |
| 2020 Q3 | 52.6 Million SEK | 22.61% |
| 2020 Q2 | 42.9 Million SEK | -17.18% |
| 2020 Q1 | 51.8 Million SEK | 1.58% |
| 2020 Q4 | 74.32 Million SEK | 41.31% |
| 2019 Q1 | 47.3 Million SEK | -18.04% |
| 2019 Q2 | 51.5 Million SEK | 8.88% |
| 2019 Q3 | 55.6 Million SEK | 7.96% |
| 2019 FY | 205.39 Million SEK | 8.04% |
| 2019 Q4 | 50.99 Million SEK | -8.28% |
| 2018 Q4 | 57.71 Million SEK | 23.58% |
| 2018 Q2 | 51.9 Million SEK | 53.55% |
| 2018 FY | 190.11 Million SEK | 42.81% |
| 2018 Q1 | 33.8 Million SEK | -19.57% |
| 2018 Q3 | 46.7 Million SEK | -10.02% |
| 2017 Q3 | 33.2 Million SEK | 3.1% |
| 2017 Q1 | 25.75 Million SEK | -5.63% |
| 2017 FY | 133.12 Million SEK | 61.06% |
| 2017 Q4 | 42.02 Million SEK | 26.58% |
| 2017 Q2 | 32.2 Million SEK | 25.01% |
| 2016 Q3 | 22.47 Million SEK | 43.88% |
| 2016 Q4 | 27.29 Million SEK | 21.47% |
| 2016 FY | 82.65 Million SEK | 24.93% |
| 2016 Q1 | 17.26 Million SEK | -15.55% |
| 2016 Q2 | 15.61 Million SEK | -9.56% |
| 2015 Q1 | 15.24 Million SEK | -17.9% |
| 2015 FY | 66.16 Million SEK | 24.38% |
| 2015 Q4 | 20.44 Million SEK | 33.14% |
| 2015 Q3 | 15.35 Million SEK | 1.67% |
| 2015 Q2 | 15.1 Million SEK | -0.92% |
| 2014 Q1 | 11.13 Million SEK | -33.73% |
| 2014 Q3 | 10.48 Million SEK | -19.34% |
| 2014 FY | 53.19 Million SEK | 18.11% |
| 2014 Q4 | 18.57 Million SEK | 77.1% |
| 2014 Q2 | 13 Million SEK | 16.79% |
| 2013 FY | 45.03 Million SEK | 74.72% |
| 2013 Q1 | 8.61 Million SEK | -24.37% |
| 2013 Q2 | 7.76 Million SEK | -9.83% |
| 2013 Q3 | 11.78 Million SEK | 51.8% |
| 2013 Q4 | 16.79 Million SEK | 42.51% |
| 2012 Q1 | 2.52 Million SEK | -30.94% |
| 2012 FY | 25.77 Million SEK | 72.88% |
| 2012 Q4 | 11.38 Million SEK | 145.71% |
| 2012 Q3 | 4.63 Million SEK | -35.94% |
| 2012 Q2 | 7.23 Million SEK | 186.08% |
| 2011 Q1 | 5.65 Million SEK | 32.01% |
| 2011 Q4 | 3.66 Million SEK | 8.79% |
| 2011 Q2 | 2.22 Million SEK | -60.59% |
| 2011 Q3 | 3.36 Million SEK | 50.96% |
| 2011 FY | 14.9 Million SEK | 4.74% |
| 2010 Q2 | 1.84 Million SEK | -33.79% |
| 2010 Q3 | 5.33 Million SEK | 189.67% |
| 2010 Q1 | 2.77 Million SEK | -12.16% |
| 2010 FY | 14.23 Million SEK | 190.57% |
| 2010 Q4 | 4.28 Million SEK | -19.62% |
| 2009 Q3 | - SEK | -100.0% |
| 2009 Q2 | 707 Thousand SEK | -31.23% |
| 2009 Q1 | 1.02 Million SEK | 365.03% |
| 2009 FY | 4.89 Million SEK | 279.42% |
| 2009 Q4 | 3.16 Million SEK | 0.0% |
| 2008 FY | 1.29 Million SEK | 0.0% |
| 2008 Q2 | 830 Thousand SEK | 0.0% |
| 2008 Q1 | - SEK | 0.0% |
| 2008 Q3 | 745 Thousand SEK | -10.24% |
| 2008 Q4 | -387.87 Thousand SEK | -152.06% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -6703.637% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 69.074% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 69.074% |
| Arcoma AB | 163.01 Million SEK | -160.476% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -108.155% |
| BICO Group AB (publ) | 2.23 Billion SEK | 81.04% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 25.679% |
| CellaVision AB (publ) | 677.29 Million SEK | 37.307% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -5032.54% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -43393.113% |
| Duearity AB (publ) | 1.65 Million SEK | -25572.007% |
| Dignitana AB (publ) | 86.06 Million SEK | -393.377% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -4022.476% |
| Getinge AB (publ) | 31.82 Billion SEK | 98.666% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -5898.838% |
| Integrum AB (publ) | 104.11 Million SEK | -307.818% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -49580.063% |
| Mentice AB (publ) | 273.61 Million SEK | -55.19% |
| OssDsign AB (publ) | 112.15 Million SEK | -278.59% |
| Paxman AB (publ) | 210.11 Million SEK | -102.085% |
| Promimic AB (publ) | 37.07 Million SEK | -1045.441% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -173922.541% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -1726.694% |
| ScandiDos AB (publ) | 60.42 Million SEK | -602.668% |
| Sectra AB (publ) | 2.96 Billion SEK | 85.672% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -175.962% |
| Senzime AB (publ) | 35.75 Million SEK | -1087.601% |
| SpectraCure AB (publ) | 318 Thousand SEK | -133426.73% |
| Stille AB | 294.89 Million SEK | -43.99% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 87.91% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 28.94% |